Beijing Luzhu Biotechnology Co., Ltd. (02480.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 13.90

From 52W high−46.46%

Volume200.00

Market capHKD 2.76B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

HKD 13.90

From 52W high

−46.46%

Volume

200.00

Market cap

HKD 2.76B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

63.1

MomentumView details →

1D Return

+2.51%

YTD Return

−41.10%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+2.51%

YTD Return

−41.10%

1Y Return

−44.13%

RSI (14)

63.1

vs 50D SMA

+3.42%

vs 200D SMA

−27.86%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.05

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 24, 2027 →

Latest newsMore news →

Green Bamboo Biotech announced that the Phase III clinical trial results of its core product LZ901 vaccine in China were published in Nature Communications on August 7, 2026, showing high protective efficacy and good safety in preventing herpes zoster in adults aged 40 and above.42d ago

Similar companies

Soleno Therapeutics, Inc.SLNO BioDlink International Company Limited01875.HK Genor Biopharma Holdings Limited06998.HK Precigen, Inc.PGEN Immunome, Inc.IMNM NewAmsterdam Pharma Company N.V.NAMS Find similar companies →

Latest newsMore news →

Green Bamboo Biotech announced that the Phase III clinical trial results of its core product LZ901 vaccine in China were published in Nature Communications on August 7, 2026, showing high protective efficacy and good safety in preventing herpes zoster in adults aged 40 and above.42d ago